RxDoctor Payments Data

Jordan Hatchett

Women's Health · Louisville, KYNPI 1710412077

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by GSK at 24.7% of the total.

$1,042in general payments, 2019–2025

Across 12 payments — averaging $86.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$257
  • Johnson & Johnson$253
  • Coherus Oncology, Inc.$125
  • AstraZeneca$120
  • Eisai Inc.$114
  • AbbVie$83
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$1,02799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,042 in reported general payments places this provider in the 65th percentile of 96 women's health providers in Kentucky.

See all women's health providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,113
Medicare patients
38
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RubracaRucaparib Camsylate14$124,018
EliquisApixaban20$12,961
Ondansetron Hcl17$1,104
Anastrozole64$1,015
Tamoxifen Citrate18$831
Lidocaine-PrilocaineLidocaine/Prilocaine31$402
Dexamethasone15$374
Letrozole23$364
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$251
Promethazine Hcl42$103
Famotidine18$88
Fluconazole14$86
Oxycodone Hcl25$71
Gabapentin14$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Clovis Oncology, Inc.Rubraca$10$124,01814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 96 women's health providers in Kentucky.

Other women's health in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →